Hospira — Merger or Acquisition (February 2007)
26 slides from Hospira's merger presentation, Feb 1, 2007
Slide 1: Mayne Pharma Acquisition
Mayne Pharma Acquisition February 1, 2007
Slide 2: Safe Harbor
Safe Harbor This material contains forward-looking statements within the meaning of the federal securities laws. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the federal securities laws. In some cases, you can identify these
Slide 3: Mayne Pharma Acquisition
Mayne Pharma Acquisition Hospira initially announced agreement to acquire Mayne Pharma Limited on Sept. 21, 2006 (Sept. 20 U.S. time) The transaction was completed on Feb. 2, 2007 (Feb. 1 U.S. time) Mayne Pharma is an excellent fit with Hospira’s strategy to invest for growth, which the company is e
Slide 4: Mayne Pharma Acquisition Benefits
Mayne Pharma Acquisition Benefits Establishes Hospira as the worldwide leader in specialty generic injectable pharmaceuticals Combines the leading generic injectable company in the U.S. with the leading generic injectable company in Europe and Australia Strengthens Hospira’s specialty injectable pha
Slide 5: Hospira and Mayne Pharma at a Glance
Hospira and Mayne Pharma at a Glance Yes No API Production Capability Yes No Potent/Cytotoxic Manufacturing 5 13 Manufacturing Facilities = 200 = 650 Sales Force = 2,000 = 13,000 Employees Worldwide 65+ countries Via direct sales: 20 Via distributors: 45+ 57 countries Via direct sales: 19 Via distri
Slide 6: Hospira & Mayne Pharma Geographic Sales Breakdown
U.S.: =85% International: =15% International: =30% U.S.: =70% U.S.: =20% International: =80% Hospira Mayne Pharma Hospira & Mayne Pharma Geographic Sales Breakdown
Slide 7: Expected Financial Impact of the Acquisition
EPS impact in 2007: slightly accretive to adjusted EPS*, dilutive to GAAP EPS Cost synergies: minimum of $50 million annually beginning in 2008 Price: AUD$4.10 per Mayne share; total of AUD$2.6 billion, or = US$2.1 billion Financing: = $200 million cash on hand; a $500 million term loan and a $1.4 b
Slide 8: Combined Company Organizational Structure
CEO – Christopher Begley Corporate Vice President, Global Strategy and Business Development – Ron Squarer formerly Senior Vice President, Global Corporate and Business Development, Mayne Pharma COO – Terrence Kearney President, Global Pharmaceuticals – Thomas Moore formerly Vice President and Genera
Slide 9: Focus on Seamless Integration
Mayne Transition Team was formed after September 2006 acquisition announcement Achieved much progress and collaboration to the extent possible during the pre-close planning phase Integration efforts have accelerated since the transaction was approved by the Australian Court on Jan. 19, 2007 Intend t
Slide 10: Mayne Pharma overview
Mayne Pharma overview Notices All information in this presentation regarding Mayne Pharma Limited has been derived from publicly available sources and has not been independently verified by Hospira. All figures are in Australian dollars, unless otherwise noted. References to FY 2005 and FY 2006 refe
Slide 11: History
History 1845 F.H. Faulding founded in Adelaide by Francis Faulding 1947 F.H. Faulding publicly listed in Australia 1984 F.H. Faulding acquired David Bull Laboratories (Mulgrave injectable facility) 2001 Mayne Group acquired F.H. Faulding 2005 Mayne Pharma demerged from Mayne Group 2007 Hospira acqui
Slide 12: Major acquisitions / joint ventures
Major acquisitions / joint ventures 2003: NaPro paclitaxel manufacturing business (Boulder, CO) 2003: Methotrexate and leucovorin from Xanodyne (for US market) 2004: MVI® (injectable vitamins) product line (US) 2004: Paxene® Europe (paclitaxel from Ivax) 2004: ROVI (Spain sales business) 2004: Wasse
Slide 13: Mayne Pharma's key strengths
Mayne Pharma’s key strengths Injectable product development Development of generic injectable oncology and oncology-related products for global registration Increasing development of more complex molecules and formulations Large molecules – i.e., peptides, extracted and fermented products Non-aqueou
Slide 14: FY 2006 sales by category
FY 2006 sales by category Pro forma sales up by 17.6% in FY 2006 Products 82% Compounding 5% Contract Manufacturing 13% EMEA 49% Asia Pac 24% N America 27% Anti-cancer 47% Anti-infective 10% Biphosphonate 8% Oncology other 6% Pain management 3% Non-oncology 26% FY 2006 sales by geographic region
Slide 15: Mayne's global presence – sales FY 2006
Mayne’s global presence – sales FY 2006 * 2006 pro forma sales revenue for the year ended 30 June 2006 Americas $217m* EMEA $391m* Asia Pacific $194m*
Slide 16: Regional overview – EMEA
Regional overview – EMEA* Direct territories: Belgium Denmark Finland France Germany Ireland Italy Netherlands Norway Portugal Spain Sweden UK 49% of revenue Sales FY 2006 A$391m (+19%) Key activities: direct sales in 13 countries; distributors in over 40 countries non-cytotoxic injectable manufactu
Slide 17: Regional overview – Asia Pacific
Regional overview – Asia Pacific* Direct territories: Australia Hong Kong Malaysia New Zealand Singapore 24% of revenue Sales FY 2006 A$194m (+22%) Key activities: direct sales in 5 countries; distributors in 3 countries cytotoxic and non-cytotoxic R&D and injectable manufacturing in Mulgrave (Austr
Slide 18: Regional overview – Americas
Regional overview – Americas* * As at 30 June 2006 Direct territories: USA Canada 27% of revenue Sales FY 2006 A$217m (+12%) Key activities: direct sales in USA and Canada Non-cytotoxic injectable manufacturing: Aguadilla, Puerto Rico API processing: Boulder, CO, USA R&D and regulatory affairs
Slide 19: Oncology continues to grow
Global growth rate by therapeutic area 2005 (%) Oncology continues to grow Source: IMS Knowledge link; note that oncology refers to IMS classes L1 and L2. 0 20 Metabolic/ alimentary Haematology Cardio- vascular Genito- urinary Anti-infective Oncology Central nervous system Respiratory
Slide 20: Growth drivers for oncology products
Growth drivers for oncology products Cancer therapeutic class was fastest growing of top eight classes Many business development opportunities for growth Internal development to alliances and in-licensing to M&A Ageing population results in increasing cancer incidence World Health Organisation (WHO)
Slide 21: Oncology products losing patent protection over the next 10 years
Significant value of certain oncology products losing patent protection over the next 10 years 28% 1,476 Eloxatin® (oxaliplatin) Selected injectable cytotoxic molecules: 10% 1,000 Zometa® (zoledronic acid) 1% 1,227 Neupogen® (G-CSF) Selected injectable oncology related therapies: -3% 153 Hycamtin® (
Slide 22: Mayne Pharma's top products in FY 2006
Mayne Pharma’s top 10 products in FY 2006 Top 10 products by sales Anti-infective Side effect reducer Anti-infective Oncology Anti-infective / Dermatology Oncology Vitamins Oncology Oncology Oncology Therapeutic area Fluconazole Leucovorin Vancomycin Methotrexate Doryx® * Carboplatin MVI Irinotecan
Slide 23: Mayne Pharma generic pipeline
Estimated total LMV of molecules filed awaiting approval US$4.2 billion In total, 46 molecules in the product pipeline * LMV (Local Market Value) refers to the annual sales of equivalent products already being sold in the market whether patented or generic. LMV is not a forecast of Mayne Pharma’s ex
Slide 24: Manufacturing facilities
Manufacturing facilities Boulder Wasserburg Zydus Cadila JV (under construction) Mulgrave Salisbury Aguadilla
Slide 25: Highly developed oncology manufacturing capabilities
Highly developed oncology manufacturing capabilities Low cost manufacturing Vertically integrated API and fill and finish site Favourable intellectual property environment Cytotoxic vials API processing Ahmedabad, India Zydus JV* Oncology focused Staff’s technical knowledge High volume capability No
Slide 26: Reconciliation of Mayne Pharma pro forma sales to statutory sales
Reconciliation of Mayne Pharma pro forma sales to statutory sales Mayne Pharma acquired from Mayne Group Limited, F.H. Faulding & Co. Ltd including its pharmaceutical businesses based in Salisbury, South Australia effective 18 November 2005 and accordingly they are not included in the financial resu